Stock Analiz

Femasys Inc. FEMY

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$1.42Market cap $12M
Open the interactive analysis →

Femasys Inc. (FEMY) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$12M, a net margin of -614.7%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -83%.

About Femasys

Femasys is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $1M in 2020 to $2M in 2025, growth of about 17.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 235% over three years (dilution for shareholders). It spends 330% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.0
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-145.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)40.8%
Revenue growth (5 yrs, per year)17.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-976.0%
ROIC (5-yr avg.)-82.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$2M$2M$2M$1M$1M$1M$1M
Net income-$12M-$19M-$19M-$14M-$11M-$8M-$7M
Free cash flow-$17M-$19M-$20M-$11M-$11M-$8M-$5M
EPS (diluted)$-1.53$-2.35$-4.25$-4.65$-4.80$-5.60$-36.00
Net margin-614.7%-812.3%-1155.0%-1329.1%-944.6%-639.0%-666.2%
ROIC—-131.5%-144.2%-55.1%-58.1%-24.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $16.50, 1062% above the current price; targets range from $10.00 to $23.00; the consensus rating is “none”; expected EPS is $-2.60 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Femasys pay a dividend?

Not currently.

Is Femasys a good stock to buy?

We do not give buy or sell advice. Femasys scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.